ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

AMYT Amryt Pharma Plc

143.00
0.00 (0.00%)
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Amryt Pharma Plc LSE:AMYT London Ordinary Share GB00BKLTQ412 ORD 6P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 143.00 151.00 170.00 - 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Amryt Pharma Share Discussion Threads

Showing 476 to 498 of 7375 messages
Chat Pages: Latest  31  30  29  28  27  26  25  24  23  22  21  20  Older
DateSubjectAuthorDiscuss
08/9/2016
11:01
Down? Do my eyes deceive me?
bigwavedave
07/9/2016
18:24
We need some good news from the company to push the share price above the 24p share price placing price and SOON! An update would be appreciated!
papillon
07/9/2016
18:22
Dividing the current AMYT share price (20.5p) by 8 gives 2.56p. Sorry JP your "The share price as it stands is about 2p in old fastnet money" is just plain wrong! 2.56p is around 25% higher than 2p. Basic arithmetic is obviously not your strong point!

To the best of my knowledge the "rip off mates rates" price was set at a 30% discount to the 24p placing price. That works out at around 17p, so the current 20.5p share price is approximately 20% above the "mates rate" price. I'm afraid your grasp of basic arithmetic is dire, JP. Did you skip mathematics at school? It appears to be so. In future I suggest you refrain from showing your complete ignorance of basic arithmetic. You're just showing yourself up.

papillon
07/9/2016
14:48
Early_Bird
Posts: 4,631
Premium Chat Member
Off Topic
Opinion: No Opinion
Price: 20.50
InterimsToday 14:15due this month I believe so not long to wait here for the next update at the very least as a footnote attached to them or as a separate release.

News on:

Prelim P3 trials commencing

Imlan marketting update

Possible Nasdaq listing application

>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>

I don't know the likelyhood of a Nasdaq listing, but biotechs are given much higher ratings on that exchange compared to AIM so BRING IT ON!

papillon
07/9/2016
12:48
LOL, Divmad. Low volume so far today. Only small trades.
papillon
07/9/2016
07:16
Well at least this mini rise is keeping Jacksonpillock off our backs.
divmad
06/9/2016
18:09
Just in the first report which looks really useful! Very grateful, thanks again.
icebreaker
06/9/2016
18:05
Icebreaker, I googled these sites.
papillon
06/9/2016
18:02
That's useful to know Pap - Thanks.
icebreaker
06/9/2016
17:57
All I know, Icebreaker, is that the patient group size will be small and that Phase III will be fast tracked because it's for an "orphan" drug treatment.
papillon
06/9/2016
17:53
Can anyone tell me whether there is a phase III programme whereby we would be able to determine the patient group size, evaluation/result parameters etc. or is this not in the public domain?

I am assuming a programme would have been put together by now.

Many thanks in advance

IB

icebreaker
06/9/2016
17:49
The AMYT Ichimoku chart is very bullish and has been so since the 12th August..



Amryt Pharma

6-Sep-16 20.250▲ Tue AMYT London

12-Aug-16
19.875 Bull Senkou Span Cross Strong

11-Aug-16
18.500 Bull Kumo Breakout

5-Aug-16
15.625 Bull Chikou Span Cross Weak

3-Aug-16
15.250 Bull Tenkan/Kijun Cross Weak

22-Jul-16
15.500 Bull Kijun Sen Cross Weak

papillon
06/9/2016
17:15
A nice little day, roll on the commencement of P3
alphabravo321
06/9/2016
15:15
We have take off!
papillon
06/9/2016
14:51
Someone has just paid full ask (20p) for a small amount.
papillon
06/9/2016
14:49
Rising up on excellent volume. Good sign. I see this breaking above my 21p IH&S neckline very soon. Bring it on. I imagine this rise on above average volume is anticipating good news flow soon. Not many shares in free float. The German charitable foundation, Directors and AXA Framlington & Alan Harris own circa 65% of the shares between them.

Three of the Directors have big share stakes (over 3%). I'd be happier if Harry Stratford also had a big share stake as well (any share stake!). Can't see any 24p options issued to him either.

papillon
06/9/2016
14:32
I could do with that right now. More realistically, I think it could have another tick or two in it before the bell.
bigwavedave
06/9/2016
13:53
If the AMYT share price isn't 50p by the end of the year then I will eat my hat (if I had one!).
papillon
06/9/2016
13:29
The true bid is currently 19.1p. The offer (online) is also creeping up.
bigwavedave
06/9/2016
13:03
All 4 x 50k trades this morning were buys even the two earliest ones marked up as sells at 18.88p because I know you could buy at 18.88p because I had a small top up just before the close late last night with money I found down the back of the sofa!
papillon
06/9/2016
12:04
Some biggish buys this morning. I do believe that AMYT is going to be a big winner for shareholders. In the short term I see my very bullish Inverse Head & Shoulders pattern progressing nicely on the chart. I expect good news soon.

From the lse bb.

Early_Bird
Posts: 4,624
Premium Chat Member
Off Topic
Opinion: No Opinion
Price: 19.25
Snippet from broker noteToday 10:18" In May 2016, Pfizer purchased Anacor
Pharmaceuticals for $5.2 billion in an all cash deal to get access
to their Eczema gel which is in a phase three trial at the
moment. Amryt has been tracking this company for some time
now as Anacor�s lead product is also a topical skincare gel
aimed at the pediatric market and just over 3 years ago their
market cap would have been sub $150m when the shares
traded at $3.19 a share as opposed to around $100 today. This
demonstrates the really exciting potential of Amryt as its
pharmaceutical product Episalvan is of interest to many of the
multinational pharma companies as it has already been
approved by the European Medicines Agency earlier this year
and will be commencing sales shortly. Furthermore, as soon as
the Amryt Phase III trial of Episalvan for Epidermolysis Bullosa
gets under way then Amryt is going to be of even more interest
to these multinational pharmaceutical companies. "

papillon
06/9/2016
10:06
...nicely bounced off 50EMA, Stochastic also on the turn, upwards & onwards ;-)
billyrayvalentine
06/9/2016
09:17
Some lifesigns
alphabravo321
Chat Pages: Latest  31  30  29  28  27  26  25  24  23  22  21  20  Older

Your Recent History

Delayed Upgrade Clock